CRP and heart failure: An exploratory analysis of the CANTOS trial suggested a dose-dependent association between canakinumab therapy and reductions in hospitalization for heart failure and the composite outcome of hospitalization and heart failure-related mortality in patients with prior MI and elevated high-sensitivity CRP levels.67 However, CANTOS was not a study focused on heart failure, where the evidence so far has been quite disappointing.